XML 45 R31.htm IDEA: XBRL DOCUMENT v3.20.2
LONG-TERM DEBT (Tables)
3 Months Ended
Oct. 31, 2020
Debt Disclosure [Abstract]  
Schedule of debt
The Company’s long-term debt consisted of the following:
(in thousands)Average Interest Rate at
October 31, 2020
Fiscal Maturity YearOctober 31,
2020
August 1,
2020
Term Loan Facility4.40%2026$1,165,000 $1,773,000 
ABL Credit Facility1.60%2024986,700 756,712 
Senior Notes6.75%2029500,000 — 
Other secured loans5.19%2024-202546,138 49,268 
Debt issuance costs, net(42,122)(45,846)
Original issue discount on debt(22,316)(35,508)
Long-term debt, including current portion2,633,400 2,497,626 
Less: current portion of long-term debt(12,813)(70,632)
Long-term debt$2,620,587 $2,426,994 
Schedule of line of credit facilities
The assets included in the Condensed Consolidated Balance Sheets securing the outstanding obligations under the ABL Credit Facility on a first-priority basis, and the unused credit and fees under the ABL Credit Facility, were as follows:
Assets securing the ABL Credit Facility (in thousands)(1):
October 31,
2020
August 1,
2020
Certain inventory assets included in Inventories and Current assets of discontinued operations
$2,476,391 $2,270,892 
Certain receivables included in Accounts receivable, net and Current assets of discontinued operations$1,123,306 $1,077,682 
(1)The ABL Credit Facility is also secured by all of the Company’s pharmacy scripts, which are included in Intangibles, net in the Condensed Consolidated Balance Sheets as of October 31, 2020 and August 1, 2020.

Unused credit and fees under the ABL Credit Facility (in thousands, except percentages):October 31, 2020
Outstanding letters of credit
$97,207 
Letter of credit fees
1.375 %
Unused credit
$1,008,288 
Unused facility fees
0.25 %